Perimenopause begins, on average, four to ten years before the final menstrual period. For most women this places the onset in the early to mid-forties — sometimes earlier. During this transition, the frequency of ovulation declines, progesterone production becomes increasingly intermittent, oestrogen fluctuates widely and unpredictably rather than declining smoothly, and the HPA axis — the stress response system — becomes progressively less stable as the stabilising influence of consistent sex hormone cycling is withdrawn.
The standard medical response to perimenopausal symptoms is, in most cases, one of three things: reassurance that this is a normal phase of life, antidepressants for mood and sleep, or hormone replacement therapy. All three can be appropriate in specific situations. None of them is based on a complete picture of what the hormonal system is actually doing. And all three share a common limitation: they are responses to symptoms rather than investigations of mechanism.
What the DUTCH Plus provides that standard investigation does not is a view inside the mechanism — not just oestrogen level, but oestrogen metabolism; not just progesterone presence or absence, but progesterone metabolites and their neurological consequences; not just cortisol as a number, but cortisol as a pattern across the day, including the morning awakening response that tells you the most about HPA axis health.
The Symptoms That Bring Women to This Conversation
Sleep & Mood
Insomnia, waking at 2–4am, inability to wind down in the evening, anxiety that feels new and unexplained, low mood, emotional reactivity that feels disproportionate, mental fog and word-finding difficulty.
Vasomotor
Hot flushes, night sweats, temperature dysregulation, palpitations. Often worse in the week before a period or in the luteal phase. Sometimes cyclical, sometimes continuous.
Cycle Changes
Irregular periods, heavier or more prolonged bleeding, shorter cycles, spotting, or cycles that skip months. These reflect the declining frequency of ovulation and the resulting progesterone insufficiency.
Body Composition
Weight gain particularly in the midline and abdomen despite unchanged diet and activity. Increased joint pain and morning stiffness. Muscle loss and reduced exercise tolerance and recovery.
What these symptoms share is that they are all attributable to the hormonal transition — but they are attributable in different ways, through different mechanisms, in different women. The anxiety and insomnia are almost always progesterone-mediated. The hot flushes and night sweats are predominantly oestrogen withdrawal effects. The midline weight gain reflects the insulin resistance that worsens when oestrogen declines. The heavy bleeding reflects oestrogen dominance relative to progesterone during anovulatory cycles. Treating all of these with the same oestrogen-forward HRT approach, without knowing the specific hormonal picture, is imprecise at best and occasionally counterproductive.
What the DUTCH Plus Actually Shows
The Oestrogen Metabolite Pathways
Oestrogen is not a single compound. It is a family of hormones — primarily oestradiol (E2), oestrone (E1), and oestriol (E3) — each of which undergoes hepatic metabolism through specific enzymatic pathways producing metabolites with very different biological activities and risk profiles.
The Three Oestrogen Metabolism Pathways
2-hydroxy pathway — produces 2-hydroxyoestrone (2-OHE1), the most protective oestrogen metabolite. Weakly oestrogenic, does not stimulate oestrogen receptors significantly, associated with lower cancer risk. The pathway promoted by cruciferous vegetables, DIM, and adequate methylation capacity.
4-hydroxy pathway — produces 4-hydroxyoestrone (4-OHE1), the most concerning metabolite. Can directly damage DNA through quinone intermediates when not adequately methylated by COMT. Associated with elevated breast and endometrial cancer risk when it accumulates. The DUTCH measures the 4-OHE1 level and critically the methylation ratio — whether the COMT enzyme is adequately converting it to its safer methoxy form.
16-hydroxy pathway — produces 16-alpha-hydroxyoestrone (16-OHE1), a potent oestrogen that stimulates receptors strongly. Promotes cell proliferation. Elevated 16-OHE1 relative to 2-OHE1 is associated with increased oestrogenic stimulation of tissues and heavier periods.
A serum oestradiol test measures total circulating oestradiol. It tells you nothing about which metabolic pathway is dominant. Two women with an oestradiol of 200 pmol/L — identical on the standard test — can have radically different metabolite profiles. One primarily metabolises through the 2-hydroxy pathway and has a protective hormonal picture. The other primarily metabolises through the 4-hydroxy pathway with impaired COMT methylation, and has accumulating genotoxic metabolites that a serum test cannot detect.
This distinction has direct implications for how HRT is approached. A woman with 4-hydroxy dominance and impaired methylation may benefit from targeted methylation support — methylfolate, B12, B6 — and DIM before or alongside any oestrogen replacement, rather than adding oestrogen into an already concerning metabolite environment.
The Progesterone Picture
Progesterone is produced after ovulation by the corpus luteum — the temporary glandular structure formed from the ovarian follicle. When ovulation does not occur, there is no corpus luteum and no progesterone surge. In perimenopause, anovulatory cycles become increasingly frequent years before the final period. A woman who appears to still be cycling — still has periods, albeit irregular — may be producing dramatically less progesterone than her cycle pattern suggests.
A serum progesterone test on day 21 captures one moment in the cycle and is a poor proxy for overall progesterone production across the luteal phase. The DUTCH measures progesterone metabolites — specifically pregnandiol and pregnanolone — which reflect the integrated production of progesterone over the collection period. Low progesterone metabolites in a woman who still has periods is confirmation that anovulatory cycles are already prevalent.
The clinical consequences of progesterone deficiency in perimenopause are specific and frequently misattributed. Progesterone’s metabolite allopregnanolone is one of the most potent positive modulators of GABA-A receptors in the brain — the same receptors targeted by benzodiazepine medications. When allopregnanolone is low, GABA-A signalling is insufficient, and the clinical result is anxiety, inability to wind down, early morning waking, and a nervous system that cannot reach parasympathetic rest. This is the neurochemical basis of perimenopausal anxiety and insomnia — and it is specifically a progesterone story, not an oestrogen story.
Most perimenopausal anxiety and insomnia is a progesterone deficiency story. Progesterone is the brain’s primary calming neurosteroid. When it declines — through declining ovulation frequency, through the pregnenolone steal of chronic stress, or both — the GABA system loses its primary endogenous modulator. Antidepressants address the symptom. Restoring progesterone addresses the cause.
The Cortisol Pattern
The DUTCH Plus measures cortisol at four time points across the day — immediately on waking, thirty minutes post-waking (the cortisol awakening response), afternoon, and evening — plus total cortisol output through urinary metabolites.
In perimenopausal women, two cortisol patterns are particularly common and clinically significant. The first is elevated evening cortisol — cortisol that should be at its lowest by 9pm is still significantly elevated, driving the inability to wind down, late-night wakening, and temperature dysregulation that drives night sweats. Evening cortisol elevation is the HPA axis failing to complete its diurnal decline — often driven by chronic psychological stress, blood glucose instability at night, or the loss of the oestrogen-mediated buffering of cortisol responses that occurs as oestrogen declines.
The second is a blunted cortisol awakening response — the normal fifty to one hundred percent morning cortisol surge is absent or minimal. This pattern is associated with exhausted HPA axis function, chronic burnout, and is often seen in women who have been managing high demands over many years and describe feeling “tired but wired” — unable to sleep properly but also unable to generate the morning energy and motivation that a healthy cortisol surge provides.
Both patterns interact directly with the sex hormone picture. Elevated cortisol — through the pregnenolone steal — diverts pregnenolone away from progesterone production, worsening the progesterone deficiency that is already present from declining ovulation. Elevated cortisol also suppresses thyroid conversion, blunts immune function, raises blood glucose, and promotes insulin resistance — all of which compound the perimenopausal picture.
The Gut Connection — Beta-Glucuronidase and Oestrogen Recirculation
Oestrogen processed by the liver in Phase Two detoxification — conjugated with glucuronic acid — is excreted through bile into the gut for elimination. This should be the end of the story. But if gut bacteria produce elevated levels of beta-glucuronidase — an enzyme that cleaves the glucuronic acid bond — that conjugated oestrogen is deconjugated back to its free, active form and reabsorbed into systemic circulation.
The clinical consequence is oestrogen recirculation: the liver has processed the oestrogen for excretion, but the gut returns it. This mechanism can maintain oestrogen dominance relative to progesterone even when total oestrogen production is declining — because the circulating oestrogen pool is being topped up by recirculated oestrogen. It is one of the reasons that heavy perimenopausal bleeding and breast tenderness can persist or worsen even as the transition progresses toward lower total oestrogen output.
The GI-MAP measures beta-glucuronidase quantitatively. Elevated beta-glucuronidase, combined with low progesterone metabolites on the DUTCH and the symptom pattern of heavy periods and breast tenderness, confirms the oestrogen recirculation mechanism. The intervention is gut-targeted: calcium-D-glucarate inhibits beta-glucuronidase directly, addressing the recirculation at source.
The Difference This Makes to Clinical Management
Standard perimenopausal management offers three options applied based on symptoms rather than hormonal mechanism. The DUTCH-informed approach offers something categorically different: an intervention architecture based on what is actually happening.
If the primary finding is progesterone deficiency with elevated evening cortisol and the pregnenolone steal as the upstream cause — the first intervention is HPA axis support: sleep protocol, stress management, adaptogens, removing ongoing cortisol drivers. Progesterone supplementation on top of an unaddressed pregnenolone steal produces temporary results because the steal continues to deplete the precursor pool.
If the primary finding is 4-hydroxy oestrogen dominance with impaired methylation — the first intervention is methylation support and DIM, before adding any oestrogen. Adding oestrogen into a system that cannot adequately detoxify 4-hydroxy metabolites is a risk that a serum oestrogen test cannot even identify as relevant.
If the primary finding is elevated beta-glucuronidase driving oestrogen recirculation — the intervention is gut-targeted, not hormone-targeted. Calcium-D-glucarate, gut ecology restoration through probiotics and prebiotics, and fibre to bind oestrogen in the gut before reabsorption can occur.
Oestrogen metabolite pathways: which metabolites are dominant, whether the 4-hydroxy pathway is generating genotoxic intermediates, whether COMT methylation is adequate.
Progesterone metabolites: whether ovulation is still occurring and at what level, confirming progesterone deficiency in women who still appear to be cycling.
Diurnal cortisol pattern: the four-point morning curve and day-long pattern that determines whether HPA dysregulation is driving progesterone depletion through the pregnenolone steal.
The integrated clinical picture: all three of the above together, read alongside the GI-MAP beta-glucuronidase marker, provides the most precise basis available for perimenopausal management — and the clearest argument for why one woman’s successful HRT protocol may be entirely inappropriate for another.
Perimenopause is a biological transition with a predictable set of mechanisms. It is not inherently pathological. But when those mechanisms are running against a background of HPA axis dysregulation, poor methylation capacity, gut dysbiosis-driven oestrogen recirculation, and nutrient deficiencies that impair detoxification — what should be a manageable transition becomes destabilising. Understanding which specific mechanisms are operating in a given woman, rather than applying population-level symptom management, is what personalised hormonal care actually means. The DUTCH Plus is the tool that makes that understanding possible.